Camber is Ready for DSCSA
Camber is fully prepared to meet the new Drug Supply Chain Security Act (DSCSA) requirements, ensuring enhanced traceability, verification, and safety across the pharmaceutical supply chain.
Learn more about how Camber prepared for DSCSA here
Recent articles
- Camber Launches Eletriptan Hydrobromide Tablets
- Camber Launches Abacavir and Lamivudine Tablets, USP
- Camber’s Parent Company, Hetero, Partners with the Gates Foundation to Supply Generic Lenacapavir for HIV Prevention
- Camber Adds 800 mg Darunavir Tablets to Product Family
- Camber Expands Portfolio with 10 New Generic Drug Launches in Q3 2025
- Camber Launches Indomethacin Suppositories
